๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500Medullary Thyroid Cancer
DrugAnlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
DrugsAnlotinib hydrochloride·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
NCT07350707Cushing s Syndrome
Peking Union Medical College Hospital
Phase 1/2
160
Beijing
2023-06-12
Recruiting
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
NCT06908291Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital
Not applicable
500
Beijing
2023-06-12
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NCT05943379NMIBC
DrugsDisitamab Vedotin·Gemcitabine
RemeGen Co., Ltd.
Phase 2
85
Beijing
2023-06-08
Recruiting
Safety and Efficacy of Ceraโ„ข Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
NCT06125327Idiopathic Pulmonary Fibrosis
Guangzhou JOYO Pharma Co., Ltd
Phase 2/3
210
Beijing
2023-06-06
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
NCT06410092Solid Tumor
Sound Biopharmaceuticals Ltd.
Phase 1
44
Beijing, Chongqing, Chengdu
2023-06-05
Recruiting
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
NCT05871762Rectal Neoplasms
Peking Union Medical College Hospital
Observational
3,705
Beijing
2023-06-04
Active, closed
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
NCT05793307Pompe Disease Infantile-Onset
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Active, closed
A Phase โ…ข Clinical Study of MIL62 in Primary Membranous Nephropathy
NCT05862233Primary Membranous Nephropathy
DrugsMIL62·Cyclosporine
Beijing Mabworks Biotech Co., Ltd.
Phase 3
150
Beijing
2023-06-02
Recruiting
Effects of Propofol on Brain Function in Patients With Parkinson's Disease
NCT05895019PD - Parkinson's Disease
DrugPropofol
Beijing Tiantan Hospital
Observational
600
Beijing
2023-06-01
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
NCT06035016HER2-positive Breast Cancer, Early-stage Breast Cancer
DrugsPyrotinib·Capecitabine
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Recruiting
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome
NCT05902416Acute Leukemia, Myelodysplastic Syndromes
Peking University People's Hospital
Observational
120
Beijing
2023-06-01
Recruiting
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093Breast Cancer
DrugsFluzoparib·Tamoxifen·Anastrozole·Exemestane
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Active, closed
Retrospective Study of Germ Cell Tumors of the Central Nervous System
NCT05836701Germ Cell Tumor of CNS
Beijing Sanbo Brain Hospital
Observational
500
Beijing
2023-06-01
Active, closed
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
NCT07149636Breast Neoplasms, Breast Self-Examination, Cancer Screening, Health Belief Model
Peking Union Medical College Hospital
Observational
3,000
Beijing
2023-06-01
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150SCLC
DrugsPumitamig·Etoposide
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
Study on Multibranched Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysm
NCT06478576Thoracoabdominal Aortic Aneurysm
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
73
Beijing
2023-06-01
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
NCT07190742Chronic Hepatitis B Virus
DrugTVAX-008
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase 2
80
Beijing
2023-06-01
Recruiting
Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community
NCT06352736Lower Urinary Tract Symptoms
Chinese PLA General Hospital
Observational
12,567
Beijing
2023-06-01
Recruiting
Tocilizumab and Tofacitinib in the Treatment of Vascular Behรงet's Syndrome
NCT05845723Aneurysm, Behcet Syndrome, Vascular Type
DrugsTofacitinib·Tocilizumab·Cyclophosphamide
Peking Union Medical College Hospital
Phase 2
81
Beijing
2023-06-01
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
DrugsIpatasertib·Tiragolumab·Divarasib·Entrectinib
Hoffmann-La Roche
Phase 3
100
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Not yet open
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
NCT05802654Early Lung Cancer, Stereotactic Body Radiotherapy
Peking University Third Hospital
Not applicable
100
Beijing
2023-06
Recruiting
Comparative Study of Prognosis and QOL Between APD-RPM and CAPD
NCT05738525End-stage Renal Disease
Chinese PLA General Hospital
Observational
750
Beijing
2023-06
Recruiting
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
NCT05917431Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Peking University Cancer Hospital & Institute
Phase 2
39
Beijing
2023-06
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
By invitation
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
NCT06186804cGvHD
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome
NCT06737666Diarrhea-predominant Irritable Bowel Syndrome
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 1
60
Beijing
2023-05-29
Recruiting
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
NCT06403943Adjuvant, Treatment, Tuberculosis
Beijing Chest Hospital
Phase 4
292
Beijing
2023-05-29
Recruiting
68Ga-P3 PET/CT Imaging in Prostate
NCT05940259Neoplasms
Peking University First Hospital
Not applicable
30
Beijing
2023-05-29
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029Osteoporotic Fractures
DrugDenosumab
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Active, closed
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
NCT05796206Systemic Lupus Erythematosus
Beijing Mabworks Biotech Co., Ltd.
Phase 2
120
Beijing
2023-05-26
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis
NCT05540938Rheumatoid Arthritis
China-Japan Friendship Hospital
Phase 4
340
Beijing
2023-05-23
Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
NCT05494502Breast Neoplasms, Mastectomy, Nerve Block, Dexmedetomidine
Peking University First Hospital
Not applicable
1,206
Beijing
2023-05-23
Recruiting
68Ga-P3 PET/CT Imaging in Malignancy
NCT05887687Neoplasms
Peking University First Hospital
Not applicable
350
Beijing
2023-05-20
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
NCT05860400Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
39
Beijing
2023-05-17
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
DrugsSteroid mouthwash (dexamethasone·MK-4830·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer ๏ผˆNORESTO Study๏ผ‰
NCT06194708Rectal Cancer
Peking Union Medical College Hospital
Observational
235
Beijing
2023-05-15
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Active, closed
Randomized Controlled Study of Programmed Weaning From NIV for AECOPD
NCT06014034Acute Exacerbation of COPD
Peking University Third Hospital
Not applicable
80
Beijing
2023-05-12
Recruiting
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
NCT05886439Lung Cancer
DrugsDurvalumab·Pembrolizumab·Tislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Recruiting
Intensive Treatment on Periodontitis in Aortic Stenosis
NCT06587971Aortic Valve Stenosis, Periodontitis
China National Center for Cardiovascular Diseases
Not applicable
920
Beijing
2023-05-10
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
DrugYK012
Excyte Biopharma Ltd
Phase 1
48
Beijing
2023-05-09
Recruiting
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
NCT05839314Nephropathy, Glomerular Diseases, Idiopathic Membranous Nephropathy
Chinese PLA General Hospital
Phase 4
480
Beijing
2023-05-09
Recruiting
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
NCT05775042IgA Nephropathy
Keymed Biosciences Co.Ltd
Phase 2
70
Beijing
2023-05-08
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
NCT05629234Cancer
DrugOsimertinib
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsSacituzumab Govitecan·Nab-paclitaxel·Capecitabine·Paclitaxel
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Active, closed
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Drugs[177Lu]Lu-PSMA-617·[68Ga]Ga-PSMA-11·ARDT
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Recruiting
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
NCT05773820Advanced Solid Tumors
DrugWJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
210
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Recruiting
Frontline of ASCT in High-risk DLBCL
NCT05831865Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Observational
175
Beijing
2023-05-03
Recruiting
Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease
NCT07498686RT-QuIC
Xuanwu Hospital, Beijing
Observational
458
Beijing
2023-05-01
Recruiting
Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease
NCT06198309Chronic Obstructive Pulmonary Disease Severe
Li An
Observational
365
Beijing
2023-05-01
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
DrugsLiposomal paclitaxel·Nedaplatin·Nab-paclitaxel·Cisplatin
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Not yet open
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsPemetrexed·Bevacizumab
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Prospective Comparative Validation Study of RUCAM and RECAM
NCT06771011Drug Induced Liver Injury
Beijing Friendship Hospital
Observational
407
Beijing
2023-05-01
Recruiting
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
NCT05833893nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma
Chinese PLA General Hospital
Phase 2
10
Beijing
2023-05-01
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Early PP Monitored by EIT in Patients With ARDS
NCT05822869Acute Respiratory Distress Syndrome
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2023-05-01
Not yet open
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
NCT05842746Glioblastoma, IDH-wildtype
Peking Union Medical College Hospital
Phase 2
74
Beijing
2023-05
Active, closed
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287Primary IgA Nephropathy
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05761028Moderate to Severe Asthma
DrugStapokibart
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3
600
Beijing
2023-04-28
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
NCT06957626Colorectal Polyp, Colorectal Cancer Recurrent, Colorectal Adenoma
Peking Union Medical College Hospital
Observational
150
Beijing
2023-04-25
Recruiting
Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion
NCT05779215Acute Ischemic Stroke
Xuanwu Hospital, Beijing
Observational
50,000
Beijing
2023-04-25
Recruiting
Effect of Gut Microbiome Intervention on Aging Via Oral FMT
NCT05598112Aging, Frailty
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase EARLY_PHASE1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
DrugsTobemstomig·Tiragolumab·Axitinib·Pembrolizumab
Hoffmann-La Roche
Phase 2
199
Beijing, Nanjing, Tianjin
2023-04-21
Recruiting
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
NCT06792162Gastric Cancer
Peking University Third Hospital
Phase 2
20
Beijing
2023-04-20
Recruiting
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
NCT05738694Renal Cell Carcinoma, Neoadjuvant
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Active, closed
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252Non-small Cell Lung Cancer
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry
NCT05598632Atrial Fibrillation, Stroke
China National Center for Cardiovascular Diseases
Observational
22,000
Beijing
2023-04-18
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfiri·Nab-paclitaxel·Gemcitabine
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
NCT05639647Gram-negative Bacterial Infections
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
DrugsTacrolimus·Zanubrutinib
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Recruiting
A Study of Telitacicept in Lupus Nephritis
NCT05680480Lupus Nephritis
RemeGen Co., Ltd.
Phase 2
120
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Liuzhou, Guiyang, Baoding
2023-04-17
Recruiting
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
NCT05772104Generalized Anxiety Disorder
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase 3
495
Beijing
2023-04-17
Recruiting
A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents
NCT05832723Myopia
Beijing Tongren Hospital
Observational
2,000
Beijing
2023-04-15
Recruiting
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853Solid Tumor, Adult
DrugsAK119·Bevacizumab
Akeso
Phase 1/2
87
Beijing
2023-04-14
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
DrugsTobemstomig·Tiragolumab·Atezolizumab
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Recruiting
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
NCT04728516Acute Coronary Syndrome, Helicobacter Pylori Infection
DrugsPantoprazole·Amoxicillin
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Active, closed
TrEatment Approach in the Multimodal Era Registry
NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH
International CTEPH Association
Observational
1,000
Beijing
2023-04-12
Recruiting
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
NCT05782270Anticoagulation, Coronary Endarterectomy
China National Center for Cardiovascular Diseases
Phase 4
202
Beijing
2023-04-11
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642Acute Ischemic Stroke
DrugLT3001 Drug
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Rows per page Showing 4201–4300 of 5484
Previous 41 42 43 44 45 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=43

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.